For research and educational purposes only. Not intended for human consumption.
CJC-1295
Well Researched- •Phase 1/2 trials 2024-2025 data
- •FDA PCAC review status (Sept 2024)
- •DAC version PK: GH 2-10x for 6+ days
Modified GRF 1-29 | Growth Hormone Releasing Hormone Analog
Overview
What is CJC-1295?
CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body's natural GH secretion patterns. Phase 1/2 trials through 2025 demonstrate dose-dependent GH increases lasting 6-8 days (with DAC version), with improvements in lean mass and fat loss. In September 2024, the FDA submitted CJC-1295 for review by the Pharmacy Compounding Advisory Committee (PCAC). Banned by WADA
Key Benefits
Preserves natural GH pulsatility without desensitization (confirmed in clinical trials), minimal side effects, precise control over GH release. DAC version increases plasma GH levels 2-10x for 6+ days and IGF-1 levels 0.5-3x for 9-11 days per injection.
Mechanism of Action
Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses. The Drug Affinity Complex (DAC) version binds albumin for extended half-life and sustained GH elevation.
Molecular Information
Pharmacokinetics
Research Indications
Natural GH Pulse Restoration
Stimulates physiological growth hormone pulses that decline with age.
IGF-1 Elevation
Increases insulin-like growth factor 1 levels through enhanced GH secretion.
Pituitary Function Support
Maintains healthy pituitary-somatotroph axis without suppression.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-Aging/Wellness | 100mcg | 2x daily (morning and bedtime) | Subcutaneous |
| Body Composition | 100-150mcg | 3x daily (morning, post-workout, bedtime) | Subcutaneous |
| Maximum GH Release | 200mcg | 2-3x daily with GHRP | Subcutaneous |
| Sleep Enhancement | 100-200mcg | Once at bedtime | Subcutaneous |
Timing: Administer 30+ minutes away from food for optimal absorption. Morning dose upon waking, evening dose before bed for best results.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean vial tops with alcohol pad and let dry
Draw 2mL bacteriostatic water for a 2mg vial (creates 100mcg per 10 units)
Inject water slowly down the side of the peptide vial
Gently roll vial to mix - do not shake vigorously
Solution should be clear - cloudy solution indicates degradation
Label with reconstitution date and concentration
Store immediately in refrigerator
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
Legitimate Source with COA
Purchase from vendors providing certificates of analysis showing >98% purity.
Proper Cold Chain Shipping
Peptide should arrive with ice packs or refrigerated shipping in hot weather.
Vacuum-Sealed Vials
Legitimate peptides create vacuum when reconstituted - water should be pulled in.
Check Expiration Dates
Lyophilized peptide typically stable for 2 years if stored properly.
Pre-Mixed Solutions
Avoid pre-reconstituted products - peptide degrades rapidly in solution.
Discolored Powder
White to off-white powder only - yellow or brown indicates degradation.
What to Expect
- •Day 1-7: Improved sleep quality, vivid dreams common
- •Week 2-4: Increased recovery from workouts, reduced DOMS
- •Week 4-8: Noticeable improvements in skin quality, minor body composition changes
- •Week 8-12: More significant lean mass gains, fat loss, improved joint comfort
- •Week 12+: Continued gradual improvements in body composition and well-being
Side Effects & Safety
Side Effects
- •Generally well-tolerated with minimal side effects at recommended doses
- •May cause temporary facial flushing or warmth for 5-10 minutes post-injection
- •Monitor blood glucose if diabetic - GH can affect insulin sensitivity
- •Not recommended for those with active cancer due to growth-promoting effects
- •Avoid if you have diabetic retinopathy or severe kidney disease
When to Stop
- •Signs of infection at injection site
- •Severe allergic reactions
- •Significant blood sugar changes
- •Active cancer diagnosis
- •Consult healthcare provider
References
5 StudiesPhase 1/2 Clinical Trials (2024-2025)
Human | Healthy adults | Multiple doses | Dose-dependent GH increases lasting 6-8 days
Clinical data demonstrates tolerability with mild side effects in healthy adults. Studies confirm the peptide preserves pulsatile GH secretion without causing desensitization, making it suitable for growth hormone deficiency treatment.
DAC Pharmacokinetic Study
Human | Single injection | Plasma monitoring | Extended GH/IGF-1 elevation
Single injection of CJC-1295 DAC increases plasma GH levels 2-10x for 6 days or longer and IGF-1 levels 0.5-3x for 9-11 days through albumin-binding mechanism.
Long-term Safety Profile of Modified GRF Analogs
Animal model | 6 months | Daily administration
No significant adverse effects on pituitary morphology or function with chronic use, supporting the safety of long-term pulsatile GHRH analog administration.
Quick Start Guide
Research Disclaimer
CJC-1295 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving CJC-1295 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of CJC-1295 for any purpose. Consult qualified professionals for any research applications.